mRNA Therapeutics Market is Estimated to be USD 45.85 billion by 2031; Driven by Innovative Therapeutic Potential

StreetInsider04-20

According to SNS Insider, the mRNA Therapeutics market will be reaching USD 45.85 billion by 2031 and will be growing at a CAGR of 1.7% over the forecast period of 2024-2031. mRNA Therapeutics Market ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428699196?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-20 00:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428699196","market":"us","top_or_hot":-1,"title":"mRNA Therapeutics Market is Estimated to be USD 45.85 billion by 2031; Driven by Innovative Therapeutic Potential","media":"StreetInsider","content":"<div>\n<p>According to SNS Insider, the mRNA Therapeutics market will be reaching USD 45.85 billion by 2031 and will be growing at a CAGR of 1.7% over the forecast period of 2024-2031.\nmRNA Therapeutics Market\n...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=23089464\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>mRNA Therapeutics Market is Estimated to be USD 45.85 billion by 2031; Driven by Innovative Therapeutic Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nmRNA Therapeutics Market is Estimated to be USD 45.85 billion by 2031; Driven by Innovative Therapeutic Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-20 00:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=23089464><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>According to SNS Insider, the mRNA Therapeutics market will be reaching USD 45.85 billion by 2031 and will be growing at a CAGR of 1.7% over the forecast period of 2024-2031.\nmRNA Therapeutics Market\n...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=23089464\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=23089464","article_id":"2428699196","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428699196","pubTimestamp":1713543000,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"According to SNS Insider, the mRNA Therapeutics market will be reaching USD 45.85 billion by 2031 and will be growing at a CAGR of 1.7% over the forecast period of 2024-2031.The messenger ribonucleic acid  therapeutics market is an expanding field with the potential to revolutionize modern medicine. Unlike traditional drugs that target specific proteins or enzymes, mRNA therapies deliver genetic instructions directly to cells, instructing them to produce the desired therapeutic proteins. This opens doors for treating a wide range of diseases, from infectious diseases like COVID-19 to chronic illnesses like cancer and heart disease.List of mRNA Therapeutics Companies Profiled in Report:. Key players in the market are actively involved in advancing mRNA technology. Companies like Moderna, BioNTech, Pfizer, and CureVac are at the forefront of developing mRNA vaccines and therapeutics. These players are engaged in strategic partnerships and collaborations to leverage expertise and accelera","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4592":"伊斯兰概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4534":"瑞士信贷持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","PFE":"辉瑞","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4007":"制药","SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4535":"淡马锡持仓","LU0058720904.USD":"联博国际健康护理基金A","LENZ":"Therapeutics","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","UHN":"United States Diesel-Heating O","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4551":"寇图资本持仓","BNTX":"BioNTech SE","BK4581":"高盛持仓","USD":"ProShares Ultra Semiconductors","SG9999001176.USD":"United Global Healthcare Acc USD"},"translate_title":"到2031年，mRNA治疗市场预计将达到458.5亿美元；创新治疗潜力驱动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"USD":1,"UHN":1,"LENZ":1,"PFE":0.9,"BNTX":0.9},"content_text":"According to SNS Insider, the mRNA Therapeutics market will be reaching USD 45.85 billion by 2031 and will be growing at a CAGR of 1.7% over the forecast period of 2024-2031.\nmRNA Therapeutics Market\nMarket Scope \nThe messenger ribonucleic acid (mRNA) therapeutics market is an expanding field with the potential to revolutionize modern medicine. Unlike traditional drugs that target specific proteins or enzymes, mRNA therapies deliver genetic instructions directly to cells, instructing them to produce the desired therapeutic proteins. This opens doors for treating a wide range of diseases, from infectious diseases like COVID-19 to chronic illnesses like cancer and heart disease.\nDownload Free Sample Report of mRNA Therapeutics Market @ https://www.snsinsider.com/sample-request/2671\nList of mRNA Therapeutics Companies Profiled in Report:\n\nBioNtech AG\nTranslate Bio Inc\nAros Therapeutics\nAstraZeneca\nPfizer plc\nSangamo therapeutics\nCureVac NV\nEthris GMBh\nEtherna Immunotherapies.\nCrisper Therapeutics\n\nDemand Analysis:\nDemand for mRNA therapeutics is driven by several factors. The success of mRNA vaccines against COVID-19 has fuelled public and investor confidence in this technology. Additionally, the rising prevalence of chronic diseases globally creates a significant market for novel therapeutic options. However, the market will be facing several challenges. An external recession could dampen investor enthusiasm and hinder funding for research and development (R&D). Manufacturing scalability and cost-effectiveness need improvement for broader accessibility of these therapies. Regulatory pathways for mRNA therapeutics are still evolving, and navigating them can be complex and time-consuming.\nmRNA Therapeutics Industry Segmentation as Follows:\nBy Application:\n\nRare genetic disease\nRespiratory disease\nInfectious disease\n\nBy Type:\n\nProphylactic vaccines\nTherapeutic Vaccines\nTherapeutic Drugs\n\nBy End User:\n\nHospitals and clinics\nResearch Organizations\n\nRegional Analysis:\nNorth America currently holds the largest market share of 55% due to strong research infrastructure, government funding for R&D, and the presence of major pharmaceutical companies. APAC region holds the maximum hopes for the companies, the current growth rate of the major economies of APAC region will be the driving factors for the market. Along with the growth rate the developments in the overall eco systems will be making market grow at an intense level despite of the economic slowdown. The CAGR predicted by SNS Insider for APAC region is 1.92% for the forecast period.\nRevenue Analysis:\n\nOverview:\n\nKey players in the market are actively involved in advancing mRNA technology. Companies like Moderna, BioNTech, Pfizer, and CureVac are at the forefront of developing mRNA vaccines and therapeutics. These players are engaged in strategic partnerships and collaborations to leverage expertise and accelerate R&D efforts. Recent developments include the exploration of self-amplifying mRNA platforms for enhanced therapeutic efficacy and the development of mRNA therapies targeting various oncological and rare disease indications.\n\nQuantitative Data\n\nThe mRNA Therapeutics Market is witnessing a push, driven by the success of COVID-19 vaccines. Leading the charge is Moderna, whose mRNA-1273 vaccine for COVID-19 generated $18.4 billion in revenue for 2022. Pfizer, partnered with BioNTech for their mRNA vaccine Comirnaty, isnt far behind, with estimated 2022 revenue from this vaccine exceeding $17 billion. These figures highlight the immense commercial potential of mRNA therapeutics, and with a growing pipeline targeting various diseases, revenue trends for key players are expected to maintain an upward path in the coming years.\nAsk Your Query Before Buying this Research Report @ https://www.snsinsider.com/enquiry/2671\nRecent Developments:\n\nModerna (August 2023): Entered a collaboration with CARsgen Therapeutics to combine their mRNA-based cancer vaccine with CAR-T cell therapy for treating various cancers.\nModerna: Received Breakthrough Therapy Designation for its melanoma vaccine (mRNA-4157/V940) currently in a Phase II clinical trial, showing promise in combination with Mercks Keytruda (cancer immunotherapy).\nProvidence Therapeutics (June 2023): Announced a collaboration with University Health Network (UHN) to develop mRNA-based vaccines and therapeutics for cancer and infectious diseases.\n\nKey Giveaways:\n\nThe mRNA therapeutics market holds immense potential for revolutionizing medicine.\nThe market is driven by the success of mRNA vaccines, rising chronic disease burden, and personalized medicine possibilities.\nChallenges include potential economic downturns, manufacturing limitations, and evolving regulations.\nNorth America leads the market, with Europe and Asia poised for significant growth.\nKey players are actively developing mRNA vaccines and therapeutics through partnerships and collaborations.\nThe future of the mRNA therapeutics market is bright. Overcoming current challenges and continued advancements in technology hold the promise of a new era in healthcare, offering patients with a wider range of effective and personalized treatment options.\n\nBuy mRNA Therapeutics Market report @ https://www.snsinsider.com/checkout/2671\nTable of Content\nChapter 1 Introduction\nChapter 2 Research Methodology\nChapter 3 mRNA Therapeutics Market Dynamics\nChapter 4 Impact Analysis (COVID-19, Ukraine- Russia war, Ongoing Recession on Major Economies)\nChapter 5 Value Chain Analysis\nChapter 6 Porter’s 5 forces model\nChapter 7 PEST Analysis\nChapter 8 mRNA Therapeutics Market Segmentation, By Application\nChapter 9 mRNA Therapeutics Market Segmentation, By Type\nChapter 10 mRNA Therapeutics Market Segmentation, By End User\nChapter 11 Regional Analysis\nChapter 12 Company profile\nChapter 13 Competitive Landscape\nChapter 14 Use Case and Best Practices\nChapter 15 Conclusion\nContinued…\nGet Sample Report of mRNA Therapeutics Market @ https://www.snsinsider.com/sample-request/2671\nAbout US:\nSNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.\nWe assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.\nContact Us: \nAkash Anand – Head of Business Development & Strategy,\n[email protected],\nPhone: +1-415-230-0044 (US) | +91-7798602273 (IND),\nWebsite: https://www.snsinsider.com/","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428699196"}